Skip to main content
Account

Peer review reports

From: Bortezomib, lenalidomide, and dexamethasone versus bortezomib, doxorubicin, and dexamethasone in newly diagnosed multiple myeloma

Original Submission
25 Mar 2024 Submitted Original manuscript
12 Jul 2024 Reviewed Reviewer Report
17 Jul 2024 Reviewed Reviewer Report
15 Aug 2024 Reviewed Reviewer Report
18 Aug 2024 Author responded Author comments - Hua Wang
26 Aug 2024 Author responded Author comments - Hua Wang
Resubmission - Version 2
18 Aug 2024 Submitted Manuscript version 2
27 Aug 2024 Author responded Author comments - Hua Wang
Resubmission - Version 3
27 Aug 2024 Submitted Manuscript version 3
28 Aug 2024 Author responded Author comments - Hua Wang
Resubmission - Version 4
28 Aug 2024 Submitted Manuscript version 4
29 Aug 2024 Author responded Author comments - Hua Wang
Resubmission - Version 5
29 Aug 2024 Submitted Manuscript version 5
Publishing
30 Aug 2024 Editorially accepted
9 Sep 2024 Article published 10.1186/s12885-024-12880-9

Learn about peer review

Back to article page

Navigation